Spotlight -

Drug Development|

Quality Systems

Theresa Natishan

Theresa Natishan is a director at Merck

Articles by Theresa Natishan

Analytical Method Comparability in Registration and Post-Approval Stages: A Risk-Based Approach

ByFrank Diana,Jeff Hofer,Marion Chatfield,Nancy Benz,Yuan Huang,Mark Argentine,Qinggang Wang,Shreekant Karmarkar,Hafez Abdel-Kader,Lakshmy M. Nair,Hui Fang,Theresa Natishan,Andrea M. Pless,Rick Burdick,Zeena Williams

October 2nd 2014

A risk-based approach is recommended for analytical method comparability for HPLC assay and impurities methods.

Latest Updated Articles

Analytical Method Comparability in Registration and Post-Approval Stages: A Risk-Based Approach
October 2nd 2014

Trending on Pharmaceutical Technology

FDA's IND Pilot Puts CMC Review First

CPHI Milan 2026: Trends in Pharma

Introducing the "PharmTech AI Pulse Check" Expert Video Series

Can AI Agents Satisfy CGMP Documentation Requirements?

Lessons For AI Governance in Quality Systems